<SEC-DOCUMENT>0000856982-24-000065.txt : 20240701
<SEC-HEADER>0000856982-24-000065.hdr.sgml : 20240701
<ACCEPTANCE-DATETIME>20240701092909
ACCESSION NUMBER:		0000856982-24-000065
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240701
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240701
DATE AS OF CHANGE:		20240701

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MERIT MEDICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000856982
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				870447695
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-18592
		FILM NUMBER:		241088503

	BUSINESS ADDRESS:	
		STREET 1:		1600 WEST MERIT PARK WAY
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
		BUSINESS PHONE:		8012531600

	MAIL ADDRESS:	
		STREET 1:		1600 WEST MERIT PARKWAY
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mmsi-20240701x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.6.2.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 7/1/2024 12:25:24 PM -->
<!-- iXBRL Library version: 1.0.8826.24652 -->
<!-- iXBRL Service Job ID: 5a147a2d-5a50-4b09-8e32-b4e42b0bab17 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mmsi="http://www.meritmedical.com/20240701" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:EntityCentralIndexKey" id="Tc_i_pX9bOrak-B4BEsX_Sj5g_2_1">0000856982</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:AmendmentFlag" id="Tc_sQqph26fYUSZHwOUnHSjQQ_3_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:EntityRegistrantName" id="Hidden_pYJls-55kkux-oHecHJSjQ">MERIT MEDICAL SYSTEMS INC</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="mmsi-20240701.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000856982</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:50.24pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_e89782ce_c799_4122_88dc_e410decb6ea3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C.&#160; 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:DocumentType" id="Narr_P1RX9SbtVkS5WWCaHw68dg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Date of Report (date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_tM4YxHx-4kuwH7IUR3tBdQ"><span style="font-size:9pt;">July 1, 2024</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mmsi-20240701x8k001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;width:279.71pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_pYJls-55kkux-oHecHJSjQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:17pt;font-style:normal;font-weight:bold;">Merit Medical Systems,&#160;Inc.</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_482e885a_2d52_4623_b7e4_21eef4425b9e"></a><a id="Tc_wOrV90hHW06w4dbisEVolQ_2_0"></a><a id="Tc_jHNOXY5On0--OdNSTAKNLQ_2_2"></a><a id="Tc_jQUoUTBLA0qVXFzDte5YNg_2_4"></a><a id="Tc_Dbe9k8dtm0Kyn0zE-GD4zA_3_0"></a><a id="Tc_GAqIQ5238kSxijtDHvGztg_3_2"></a><a id="Tc_1eObSwBbo0S99IbwxQVEhg_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_FTsM-g86wUi02lVDOQhudA_1_0"><b style="font-size:9pt;font-weight:bold;">Utah</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:EntityFileNumber" id="Tc_HxLe-KpLPUq6nZ2XnySRcg_1_2"><b style="font-size:9pt;font-weight:bold;">0-18592</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:EntityTaxIdentificationNumber" id="Tc_FMbELaq2I0mXIJHakkuCQA_1_4"><b style="font-size:9pt;font-weight:bold;">87-0447695</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer</p></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">incorporation or organization)</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_7d471683_06d1_45fe_9287_288340eace6c"></a><a id="Tc_4p-88nwmi0u4tWZGHMW-5Q_2_0"></a><a id="Tc_C53iUyaeL0CtkaHWaEM8gQ_3_0"></a><a id="Tc_ya-1yqOy80qKWZ17OFfDdA_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:EntityAddressAddressLine1" id="Tc_kS_is8bVQkqLhGJon85lRg_1_0"><b style="font-size:9pt;font-weight:bold;">1600 West Merit Parkway</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:EntityAddressCityOrTown" id="Narr_Hc6qjCrGTEKRnf33hFq-Hg"><b style="font-size:9pt;font-weight:bold;">South Jordan</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_-x6EaZKFCkmeT_nV7l4JQQ"><b style="font-size:9pt;font-weight:bold;">Utah</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:EntityAddressPostalZipCode" id="Tc_Hn8jQwmiEE-n-3r81lG68Q_2_2"><b style="font-size:9pt;font-weight:bold;">84095</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:CityAreaCode" id="Narr_yYgtQiVQeECS0bD2pecAfA"><b style="font-size:9pt;font-weight:bold;">801</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:LocalPhoneNumber" id="Narr_-wP1Btmd5U2rQP9ovOYC3w"><b style="font-size:9pt;font-weight:bold;">253-1600</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant's telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_elJjpXYbt0aCo3jTpcgACA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_7ss1jZzLqUGKfAVGZTuYVA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_k_KLlDbtjEKT6RzzYQTudA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_oNIyKZtWDUWSMxZ6Q75-wQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_e1adca4e_7a42_4339_9783_775404ac1f0f"></a><a id="Tc_Qd0NBaPQkkOshvg96FDx7w_1_0"></a><a id="Tc_QCsZwH10iE6yvYDDYFSIUg_1_2"></a><a id="Tc_prYCnDRUd0KSfd-BWXCZVQ_1_4"></a><a id="Tc_GvKMdWcol02xnvR_b0BaMQ_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:42.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Title&#160;of&#160;each&#160;class</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:20.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Trading&#160;Symbol(s)</p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</p></td></tr><tr><td style="vertical-align:top;width:31.7%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:Security12bTitle" id="Tc_sN-qQMH8DEWIU7of4jvcdg_2_0"><span style="font-size:9pt;">Common Stock, no par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:TradingSymbol" id="Tc_1iSQgvWa8kqoxIaRRi2V3A_2_2"><span style="font-size:9pt;">MMSI</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.39%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" name="dei:SecurityExchangeName" id="Narr_xly9DxZ8X0a8xHWB4kI4xg"><span style="font-size:9pt;">NASDAQ</span></ix:nonNumeric><span style="font-size:9pt;"> Global Select Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_pa2-Xs1vukeGz5KIpODOsQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_361b6200_d94a_4d2b_b619_2ba8dadab735"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information included in this Current Report on Form 8-K (the &#8220;Current Report&#8221;) contains forward-looking statements about Merit Medical Systems, Inc., a Utah corporation (&#8220;Merit&#8221;), that involve substantial risks and uncertainties. Merit intends such statements, and all subsequent forward-looking statements attributable to Merit, to be expressly qualified in their entirety by these cautionary statements and covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). All statements included in this Current Report, other than statements of historical fact, are forward-looking statements for purposes of these provisions. These statements involve known and unknown risks, uncertainties and other factors that may cause Merit&#8217;s actual results, levels of activity, performance or achievement to be materially different from those expressed or implied by the forward-looking statements, including those described in Merit&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 and Merit&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, and subsequent filings with the SEC. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;objective&#8221; or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. However, not all forward-looking statements contain such identifying words.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All forward-looking statements included in this Current Report speak only as of the date made, are based on information available to Merit as of such date, and are subject to change. Merit assumes no obligation to update or revise any forward-looking statement. If Merit does update or correct one or more forward-looking statements, readers should not conclude that Merit will make additional updates or corrections. Merit&#8217;s actual results will likely differ, and may differ materially, from anticipated results. Readers should not unduly rely on any such forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_08824d09_7403_4671_8f63_b65f0d528806"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1.01. &#160;Entry into a Material Definitive Agreement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July 1, 2024, Merit entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with EndoGastric Solutions, Inc., a Delaware corporation (&#8220;EGS&#8221;), pursuant to which Merit acquired the EsophyX&#174; Z+ device and various assets related thereto (collectively, the &#8220;Acquisition&#8221;), which are designed to deliver a durable, minimally invasive non-pharmacological treatment option for patients suffering from gastroesophageal reflux disease. Merit acquired the purchased assets identified under the Purchase Agreement for a purchase price of $105 million, plus the assumption or reimbursement of certain liabilities of EGS, which amounts Merit financed at closing through borrowings under its long-term credit facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Purchase Agreement contains customary representations and warranties, as well as customary indemnification provisions and post-closing covenants. The representations and warranties are insured pursuant to a buyer-side representation and warranty insurance policy (the &#8220;RWI&#8221;), subject to standard exceptions and limitations, obtained by Merit in connection with the Acquisition. Recovery under the RWI is Merit&#8217;s sole recourse for breaches of representations and warranties, other than with respect to fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At the closing of the Acquisition, Merit and EGS entered into various agreements to facilitate the transition of the acquired assets and associated business operations to Merit, including a Transition Services Agreement and a Contract Manufacturing Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The foregoing summary of the principal terms of the Purchase Agreement is not complete and is qualified in its entirety by the actual terms and conditions of the Purchase Agreement, a copy of which Merit intends to file in a future filing with the SEC. The representations, warranties, and other terms contained in the Purchase Agreement were made solely for the purposes of such agreement and as of specified dates, were solely for the benefit of the parties to the Purchase Agreement, and may be subject to limitations agreed upon by the contracting parties. Those representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the Purchase Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Purchase Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of Merit, EGS, or any of their respective subsidiaries or affiliates. Accordingly, investors should not rely on the representations and warranties as characterizations of the actual state of facts, since (i) they were made only as of the date of the Purchase Agreement or prior, specified dates, (ii) in some cases they are subject to qualifications with respect to materiality, knowledge and/or other matters, and (iii) they may be modified in important part by the underlying exhibits and schedules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_497f0c96_8682_4d34_88dc_0b404053c9b3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 2.02.  Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On July 1, 2024, Merit issued a press release announcing the Acquisition and updating its 2024 Fiscal Year Guidance in light of the Acquisition. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><a id="_a3489945_b319_4879_af9f_7d035d5a82d6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 7.01 Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July 1, 2024, Merit issued the attached press release (Exhibit 99.1) announcing the Acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information contained in Item 2.02 above and this Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act or the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Merit is making reference to non-GAAP financial information in the attached press release. A quantitative reconciliation of such non-GAAP financial information to comparable GAAP financial information is not available without unreasonable effort.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4d070440_9921_471a_9fd3_1a1e9c70e24f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 9.01. &#160;Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:34.5pt;"><td style="vertical-align:bottom;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;NUMBER</b></p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION</b></p></td></tr><tr style="height:14.5pt;"><td style="vertical-align:top;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">99.1</p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mmsi-20240701xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated July 1, 2024, entitled &#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Merit Medical </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Announces Asset Purchase Agreement with EndoGastric Solutions, Inc.&#8221;</span></a></p></td></tr><tr style="height:15.4pt;"><td style="vertical-align:top;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">104</p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_db270cfa_c35d_4d0d_8197_9158b5bf4fb1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.8%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">MERIT MEDICAL SYSTEMS,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: July 1, 2024</p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#000000;">/s/ Brian G. Lloyd</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;border-top:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian G. Lloyd</p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Legal Officer and Corporate Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>mmsi-20240701xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 7/1/2024 12:25:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 7.5pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EXHIBIT 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"><img src="mmsi-20240701xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:97.75pt;width:468pt;"></font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt;"><div style="display:inline-block;width:468pt;"><div style="left:0pt;padding-bottom:1.05pt;position:relative;top:0pt;width:468pt;"><div style="left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:468pt;"><div style="left:0pt;position:relative;text-indent:0pt;top:0pt;"><div align="left"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:16pt;height:max-content;line-height:1.28;margin-bottom:0pt;margin-top:0pt;padding-left:0pt;padding-right:0pt;text-align:left;width:100%;"><tr style="height:1pt;"><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:49.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:49.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:53.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:58.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:119.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:137.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:49.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:49.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:53.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:58.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:119.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:137.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:49.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:49.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:53.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:58.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:119.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contacts:</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:137.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:49.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:49.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:53.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:58.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:119.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PR/Media Inquiries:</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Sarah Comstock&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit Medical&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:137.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Investor Inquiries:</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Mike Piccinino, CFA, IRC&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Westwicke - ICR&#160;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:49.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:49.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:53.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:58.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:119.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">+1-801-432-2864&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:137.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">+1-443-213-0509&#160;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:49.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:49.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:53.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:58.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:119.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><u style="color:#0000ff;font-family:'Times New Roman','Times','serif';text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">sarah.comstock@merit.com</u><font style="color:#0000ff;font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:137.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><u style="color:#0000ff;font-family:'Times New Roman','Times','serif';text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">mike.piccinino@westwicke.com</u><font style="color:#0000ff;font-family:'Times New Roman','Times','serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:left;width:100%;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">Merit Medical Announces Asset Purchase Agreement with EndoGastric Solutions, Inc.</b><sup style="font-size:10.5pt;font-weight:bold;vertical-align:top;">&#174;</sup><sup style="font-size:10.5pt;vertical-align:top;">&#160;</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Asset acquisition expands Merit&#8217;s endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD).</i><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:normal;">&#160;</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Asset acquisition projected to add approximately $30 million of revenue, on an annualized basis, in key gastrointestinal endoscopy market that leverages existing commercial footprint.</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Merit reaffirms full-year 2024 financial guidance on standalone basis and updates full-year 2024 financial guidance to include projected partial-year impact from this acquisition.</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 36pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:10pt;text-align:justify;background:#ffffff;margin:0pt;">SOUTH JORDAN, Utah, July 1, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced it has executed an asset purchase agreement with EndoGastric Solutions, Inc. for a total cash consideration of approximately $105 million. EndoGastric Solutions&#8217; EsophyX<sup style="font-size:8.25pt;vertical-align:top;">&#174;</sup> Z+ device delivers a durable, minimally invasive non-pharmacological treatment option for patients suffering from GERD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><font style="color:#020a27;">GERD is a digestive disorder that occurs when the lower esophageal sphincter doesn&#8217;t tighten correctly, allowing acid from the stomach to enter the esophagus. When this occurs chronically, it can result in serious health conditions, such as esophageal damage and cancer. The EsophyX Z+ device treats GERD by restoring the body&#8217;s reflux barrier.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;">&#8220;This acquisition is consistent with our Continued Growth Initiatives. It enhances our product portfolio in existing clinical specialties while expanding our global footprint in the multi-billion-dollar gastrointestinal market.&#8221; said Fred P. Lampropoulos, Merit&#8217;s Chairman and Chief Executive Officer. &#8220;We look forward to helping more patients by providing clinicians with a sustained and minimally invasive treatment option for chronic GERD.&#8221;</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Mr. Lampropoulos continued: &#8220;In addition to the strong strategic rationale, we believe the financial profile of this acquisition is compelling. While modestly dilutive to our full year 2024 non-GAAP profitability given the partial-year contribution, we expect the acquisition to be accretive to our non-GAAP gross and operating margins*, non-GAAP net income* and non-GAAP EPS* in the first full year post-closing. Importantly, we reaffirmed our full-year 2024 financial guidance on a stand-alone basis and we look forward to discussing this acquisition and our updated outlook for 2024 on our second quarter earnings report on August 1, 2024.&#8221; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">*&#160;Non-GAAP net income; non-GAAP earnings per share; non-GAAP gross margin; non-GAAP operating margin and constant currency revenue are non-GAAP financial measures. A description of these financial measures is included under the heading &#8220;Non-GAAP Financial Measures&#8221; below. </i><font style="font-size:11pt;"><a name="_Hlk137117716"></a></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">A quantitative reconciliation of such financial measures to comparable GAAP financial measures is not available without unreasonable effort.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">About EsophyX Z+ Treatment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">By restoring the body&#8217;s reflux barrier, the acquired EsophyX Z+ device is designed to provide relief of GERD symptoms and reduce acid reflux that can cause long-term complications and risk. This is accomplished under endoscopic visualization during a minimally invasive procedure called Transoral Incisionless Fundoplication (TIF 2.0). Recently, </font><font style="color:#020a27;font-size:11pt;">the American Gastroenterology Association released a clinical practice update on the evaluation and management of GERD and listed TIF 2.0 as an effective endoscopic option in carefully selected patients.</font><sup style="color:#020a27;font-size:6.37pt;vertical-align:top;">2</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;">TIF 2.0 can also be combined with a surgical hiatal hernia repair, in a procedure referred to as Concomitant Transoral Incisionless Fundoplication (cTIF). During cTIF, an interventional gastroenterologist and a surgeon collaborate to bridge the treatment gap between medication and more invasive-surgical fundoplication.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Summary:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The assets acquired from EndoGastric Solutions generated approximately $26 million of revenue over the twelve-month period ended December 31, 2023. The acquired assets are expected to contribute revenue, from closing date through December 31, 2024, in the range of $13 to $15 million and are expected to dilute Merit&#8217;s previously forecasted non-GAAP operating margin, non-GAAP net income and non-GAAP earnings per share, inclusive of approximately $2.7 million of lower interest income on cash balances used for the total purchase consideration and excluding approximately $6.5 million of non-cash and non-recurring transaction-related expenses, and to be dilutive to Merit&#8217;s full-year 2024 GAAP net income and GAAP earnings per share. The acquisition is expected to be accretive to non-GAAP gross margin, non-GAAP operating margin, non-GAAP net income and non-GAAP earnings per share in the first full-year post close, but dilutive to Merit&#8217;s GAAP net income and earnings per share for that period. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Updated Fiscal Year 2024 Financial Guidance</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit&#8217;s updated full-year 2024 financial guidance now reflects the forecasted impacts of the acquisition of EndoGastric Solutions from the closing date through December 31, 2024. Merit is reaffirming prior full-year 2024 financial guidance ranges for the stand-alone Merit business previously announced on April 30, 2024. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Based upon the information currently available to Merit&#8217;s management, for the&#160;year ending December&#160;31, 2024, after giving effect to the projected contribution of the assets acquired from EndoGastric Solutions, but absent material acquisitions, non-recurring transactions or other factors beyond Merit&#8217;s current expectations,&#160;Merit now expects the following financial results:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue and Earnings Guidance* </i></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:34.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Updated Guidance</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">(1)</sup></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:34.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Prior Guidance</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">(2)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Year Ending</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">% Change </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Year Ending</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">% Change </b></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Financial Measure</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Y/Y</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Y/Y</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Net Sales</b></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.95%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$1.324&#160;- $1.340 billion</b></p></td><td style="vertical-align:bottom;width:12.38%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5% - 7%</b></p></td><td style="vertical-align:bottom;width:21.95%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$1.312&#160;- $1.325 billion</b></p></td><td style="vertical-align:bottom;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4% - 5%</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';">Cardiovascular Segment</font></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-size:9pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$1.272&#160;- $1.285 billion</font></p></td><td style="vertical-align:bottom;width:12.38%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4% - 5%</font></p></td><td style="vertical-align:bottom;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$1.272&#160;- $1.285 billion</font></p></td><td style="vertical-align:bottom;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4% - 5%</font></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';">Endoscopy Segment</font></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-size:9pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.95%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$53.3&#160;- $55.7 million</font></p></td><td style="vertical-align:bottom;width:12.38%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">45% - 51%</font></p></td><td style="vertical-align:bottom;width:21.95%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$39.7&#160;- $40.1 million</font></p></td><td style="vertical-align:bottom;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">8% - 9%</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-size:9pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-size:9pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Non-GAAP</b></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.95%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.38%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.95%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';">Earnings Per Share</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-size:9pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$3.22 - $3.31</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">7% - 10%</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$3.28 - $3.35</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">9% - 11%</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;background:#ffffff;">*Percentage figures approximated; dollar figures may not foot due to rounding</i></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96.2%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:18.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:0.75pt;"><td style="vertical-align:bottom;width:25.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:top;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:19.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:top;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">2024 Net Sales Guidance - % Change from Prior Year (Constant Currency) Reconciliation* </i></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Updated Guidance</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Prior Guidance</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">(2)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:60.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Low</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">High</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Low</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">High</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2024 Net Sales Guidance - % Change from Prior Year (GAAP) </font></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5.3%</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">6.6%</font></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4.3%</font></p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5.4%</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Estimated impact of foreign currency exchange rate fluctuations</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">0.5%</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">0.5%</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">0.5%</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">0.5%</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2024 Net Sales Guidance - % Change from Prior Year (Constant Currency) </font></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5.8%</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">7.1%</font></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4.8%</font></p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5.9%</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;background:#ffffff;">*Percentage figures approximated and may not foot due to rounding</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:1.19;padding-bottom:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">&#160;</font><i style="color:#293849;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;">(1)</i><sup style="color:#293849;font-family:'Times New Roman','Times','serif';font-size:4.5pt;font-style:italic;vertical-align:top;"> </sup><i style="color:#293849;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;">&#8220;Updated Guidance&#8221; reflects Merit&#8217;s full-year 2024 financial guidance on standalone basis, plus the forecasted impacts of the acquisition of EndoGastric Solutions, Inc. from closing date through December 31, 2024.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><i style="color:#293849;font-family:'Times New Roman','Times','serif';font-style:italic;">(2) &#8220;Prior Guidance&#8221; previously introduced on April 30, 2024, and reflects Merit&#8217;s full-year 2024 financial guidance on a standalone basis, excluding the acquisition of the assets of EndoGastric Solutions.</i><font style="color:#293849;font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of items such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, corporate transformation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reliably predict the impact of these items and Merit believes inclusion of a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit&#8217;s financial guidance for the&#160;year ending December&#160;31, 2024 is subject to risks and uncertainties identified in this release and Merit&#8217;s filings with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:10pt;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Quarter of Fiscal Year 2024 Financial Results Conference Call:</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:1.19;padding-bottom:10pt;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Merit will release its financial results for the quarter ended June 30, 2024, after the close of the stock market on Thursday, August 1, 2024 and will host a conference call at 5:00&#160;p.m. Eastern that day (4:00&#160;p.m. Central, 3:00&#160;p.m. Mountain, and 2:00&#160;p.m. Pacific). </font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;">To access the conference call, please pre-register using the following </b><b style="color:#4472c4;font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;">link</b><b style="color:#4472c4;font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;">. </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;">Registrants will receive confirmation with dial-in details. </b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">A live webcast and slide deck will also be available at merit.com.</font><font style="color:#293849;font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Advisors:</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Oppenheimer &amp; Co. acted as a financial advisor to Merit. Parr Brown Gee &amp; Loveless P.C. served as legal advisor to Merit. Cooley LLP served as legal advisor to EndoGastric Solutions, Inc.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-GAAP Financial Measures</u><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Although Merit&#8217;s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America, Merit&#8217;s management believes that the non-GAAP financial measures referenced in this release may provide investors with useful information regarding the underlying business trends and performance of Merit&#8217;s ongoing operations and can be useful for period-over-period comparisons of such operations. Non-GAAP financial measures referenced in this release include:&#160;</font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:10pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">constant currency revenue;&#160;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:10pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">non-GAAP gross profit and margin;&#160;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:10pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">non-GAAP operating income and margin;&#160;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:10pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">non-GAAP net income; and&#160;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">non-GAAP earnings per share.&#160;</font></div><div style="margin-top:10pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit&#8217;s management team uses these non-GAAP financial measures to evaluate Merit&#8217;s profitability and efficiency, to compare operating and financial results to prior periods, to evaluate changes in the results of its operating segments, and to measure and allocate financial resources internally. However, Merit&#8217;s management does not consider such non-GAAP measures in isolation or as an alternative to measures determined in accordance with GAAP.&#160;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Readers should consider non-GAAP measures referenced in this release in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit&#8217;s net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of non-GAAP earnings per share, non-GAAP gross profit and margin, non-GAAP operating income and margin, and non-GAAP net income because such amounts in any specific period may not directly correlate to the underlying performance of Merit&#8217;s business operations and can vary significantly between periods as a result of factors such as acquisition or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, corporate transformation expenses, governmental proceedings or changes in tax or industry regulations, gains or losses on disposal of certain assets, and debt issuance costs. Merit may incur similar types of expenses in the future, and the non-GAAP financial information referenced in this release should not be viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures referenced in this release may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to their most directly comparable GAAP financial measures and not to rely on any single financial measure to evaluate Merit&#8217;s business or results of operations.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Constant Currency Revenue&#160;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit&#8217;s constant currency revenue is prepared by converting the current-period reported revenue of subsidiaries whose functional currency is a currency other than the US dollar at the applicable foreign exchange rates in effect during the comparable prior-year period and adjusting for the effects of hedging transactions on reported revenue, which are recorded in the US dollar.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Non-GAAP Gross Profit and Margin&#160;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Non-GAAP gross profit is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets and inventory mark-up related to acquisitions. Non-GAAP gross margin is calculated by dividing non-GAAP gross profit by reported net sales.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Non-GAAP Operating Income and Margin&#160;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Non-GAAP operating income is calculated by adjusting GAAP operating income for certain items which are deemed by Merit&#8217;s management to be outside of core operations and vary in amount and frequency among periods, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, corporate transformation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. Non-GAAP operating margin is calculated by dividing non-GAAP operating income by reported net sales.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Non-GAAP Net Income&#160;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Non-GAAP net income is calculated by adjusting GAAP net income for the items set forth in the definition of non-GAAP operating income above, as well as for expenses related to debt issuance costs, gains or losses on disposal of certain assets, changes in tax regulations, and other items.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Non-GAAP EPS</i><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Non-GAAP EPS is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ABOUT MERIT</u><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,000 people worldwide.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Statements contained in this release which are not purely historical, including, without limitation, statements regarding Merit&#8217;s forecasted plans, revenues, net sales, net income (GAAP and non-GAAP), operating income and margin (GAAP and non-GAAP), gross profit and margin (GAAP and non-GAAP), earnings per share (GAAP and non-GAAP), and other financial measures, future growth and profit expectations or forecasted economic conditions, or the implementation of, and results which may be achieved through, Merit&#8217;s Continued Growth Initiatives program or other expense reduction initiatives, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to risks and uncertainties such as those described in Merit&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 (the &#8220;2023 Annual Report&#8221;) and other filings with the SEC. Such risks and uncertainties include inherent risks and uncertainties associated with Merit&#8217;s integration of the assets and operations acquired from EndoGastric Solutions and its ability to achieve anticipated financial results, product development and other anticipated benefits of the EndoGastric Solutions acquisition; uncertainties as to whether Merit will achieve sales, gross and operating margins, net income and earnings per share performance consistent with its forecasts associated with that acquisition; disruptions in Merit&#8217;s supply chain, manufacturing or sterilization processes; reduced availability of, and price increases associated with, commodity components and other raw materials; adverse changes in freight, shipping and transportation expenses; negative changes in economic and industry conditions in the United States or other countries, including inflation; risks relating to Merit&#8217;s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; risks associated with Merit&#8217;s ongoing or prospective manufacturing transfers and facility consolidations; fluctuations in interest or foreign currency exchange rates; risks and uncertainties associated with Merit&#8217;s information technology systems, including the potential for breaches of security and evolving regulations regarding privacy and data protection; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; consequences associated with a Corporate Integrity Agreement executed between Merit and the U.S. Office of Inspector General &#8211; Department of Health and Human Services; difficulties, delays and expenditures relating to development, testing and regulatory approval or clearance of Merit&#8217;s products, including the pursuit of approvals under the European Union Medical Device Regulation, and risks that such products may not be developed successfully or approved for commercial use; litigation and other judicial proceedings affecting Merit; the potential of fines, penalties or other adverse consequences if Merit&#8217;s employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; restrictions on Merit&#8217;s liquidity or business operations resulting from its debt agreements; infringement of Merit&#8217;s technology or the assertion that Merit&#8217;s technology infringes the rights of other parties; product recalls and product liability claims; changes in customer purchasing patterns or the mix of products Merit sells; laws and regulations targeting fraud and abuse in the healthcare industry; potential for significant adverse changes in governing regulations, </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">including reforms to the procedures for approval or clearance of Merit&#8217;s products by the U.S. Food &amp; Drug Administration or comparable regulatory authorities in other jurisdictions; changes in tax laws and regulations in the United States or other jurisdictions; termination of relationships with Merit&#8217;s suppliers, or failure of such suppliers to perform; concentration of a substantial portion of Merit&#8217;s revenues among a few products and procedures; development of new products and technology that could render Merit&#8217;s existing or future products obsolete; market acceptance of new products; dependance on distributors to commercialize Merit&#8217;s products in various jurisdictions outside the United States; volatility in the market price of Merit&#8217;s common stock; modification or limitation of governmental or private insurance reimbursement policies; changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable environmental laws; changes in key personnel; work stoppage or transportation risks; failure to introduce products in a timely fashion; price and product competition; fluctuations in and obsolescence of inventory; and other factors referenced in the 2023 Annual Report and other materials filed with the SEC.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this release are made only as of the date of this release, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-bottom:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TRADEMARKS</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:10pt;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc.,&#8239;its subsidiaries, or its licensors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:10pt;text-align:justify;background:#ffffff;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">REFERENCES&#160;</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:10pt;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1. Sharma et al. 2023. &#8220;Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett&#8217;s Esophagus, and Barrett&#8217;s Esophagus&#8211;Related Neoplasia in the United States</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">.&#8221; Journal of Health Economics and Outcomes Research</i><font style="font-family:'Times New Roman','Times','serif';"> 10, no. 1 (March): 51 &#822; 58. Accessed June 11, 2024. </font><font style="font-family:'Times New Roman','Times','serif';">doi: 10.36469/001c.68191. (PMID: 58829388)</font><font style="font-family:'Times New Roman','Times','serif';">2.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2. Yadlapati, Gyawali, and Pandolfino. 2022. &#8220;AGA Clinical Practice Update on the Personalized Approach to the Evaluation and </font><font style="display:inline-block;width:11.47pt;"></font><font style="font-family:'Times New Roman','Times','serif';">Management of GERD: Expert Review.&#8221; </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Clinical Gastroenterology and Hepatology</i><font style="font-family:'Times New Roman','Times','serif';"> 20, no. 5 (May): 984 &#822; 94.e1. Accessed June 11, 2024. </font><font style="font-family:'Times New Roman','Times','serif';">doi: 10.1016/j.cgh.2022.01.025. (PMID: </font><font style="font-family:'Times New Roman','Times','serif';">35123084).</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>mmsi-20240701x8k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmsi-20240701x8k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !# 74# 2(  A$! Q$!_\0
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M/V@/AI874MM<>/?#T4\3%70ZC%E2.HZU#_PT7\+O^B@>'?\ P8Q_XU/MJ?\
M,OO-EEV-:NJ,O_ 7_D>BT5B^&?&WA[QK;-/X?US3M:A3[SV%TDVWZ[2<?C6O
M//':P2332)##&I=Y)&"JJ@9))/0#UK5--73..=.=.7)--/L]Q]%>>2?M$?"^
M*1D;X@>'0RG!']HQ'G\Z;_PT7\+O^B@>'?\ P8Q_XUE[:G_,OO.S^SL;_P ^
M9?\ @+_R/1:*\Z_X:+^%W_10/#O_ (,8_P#&E7]HKX7NP4?$#P[DG _XF,7^
M-'MJ7\R^\?\ 9V-_Y\R_\!?^1Z)145I=P7]K%<VL\=S;3*'CFA<.CJ>001P0
M?45S?C/XJ>#OAU);Q^)_$^E:#+<#,,=_=)$[CID*3G'OTK1R45=O0Y*=&K6G
M[.G%N79*[^XZFBJVFZE::Q807UA=07UE.H>*YMI!)'(IZ%6!((]Q7.>*_BUX
M)\"WJV?B+Q;HVB7C+N%O?7T<4F.QVDYQ[T.48J[>@4Z%6K/V=.#<NR3;^XZR
MBO-_^&D_A3_T47PU_P"#.+_XJM/PW\;/A_XPU---T3QKH6J:A)]RUM=0B>1_
M]U0<G\*A5:;=E)?>=,LOQD(N4Z,DEUY7_D=K16)XK\<>'? EBEYXCUS3]"M9
M&V)+J%RD*NWHNXC)]A7)K^TA\*G8*/B)X:R?^HG%_P#%4Y5(1=I22(I8/$UH
M\]*E*2[I-K\#T>BL3P]XX\.>+1G0_$&EZSQG_0+R.? _X"36W5IIJZ.:<)TY
M<LU9^845B^)_&WA[P3;Q3^(==TW0X96VQR:C=I '/HNXC/X5I:?J-IJUE#>6
M-U#>V<R[XKBWD$D<B^JL,@CZ4<RO:^HW3FH*HXOE?7I]Y8HI&8(I9B%51DDG
M  KB-4^.GPYT6\-K?^._#EK<@X,4FJ0AE/H1NX_&E*48_$[%TJ%6N[4H.3\D
MW^1W%%9VA>)-(\46?VO1M4LM6M?^>]C<),GYJ2*T:::>J,I1E!N,E9A17,>*
M/BCX.\$W*VWB#Q5HVBW+8(@O[Z*%R#WVLP.*UM"\1Z3XHL1>Z-JEEJUF3@7%
MC<)-'GTW*2*2E%OE3U-94*L8*K*#47UL[?>:-%8_B#QAHGA7R1JVI6]BTV3&
MDC?,P'WF"CG:,C+=!D9-:=K=0WMM%<6TT=Q;RH)(Y8F#(ZD9# C@@CN*=TW:
MY#ISC%3:=GL^A+1113,SY:_X*+?\D.TK_L/0?^B9J_.2OT;_ ."BW_)#M*_[
M#T'_ *)FK\Y*^3S+_>'Z(_I;@+_D2Q_Q2_0*]@^"VAZ=X4\-ZY\5/$=C!J&G
M:,PL=$TZ[7=%J&JN,H&7^)(E^=A]/2O./!OA'4_'WBO2O#FCQ>=J>I7"V\*G
MHI/5V]%4 L3Z UZ-\8=5B\7^+O#OPU\"HU_H'AYAH^E)'UU"\=L3W1QU,DF>
M>RKGH:X::Y5S_=Z_\#_(^JS"?MI+!Q=E)7F]K06^O3F?NKRYFMCW[]ENZU;]
MJNZUA?BA86OB?2-!N+:[L+^2TB@:&YRQ-L"BC=$5P6C.1]W/45])_'[PY\/V
M^%NH7OCC2;:XT#1D6[6-$".&1@4CC(Y&\X3 ZAL=ZU?@A\*;'X,?#;2?"]F5
MEE@3S;RY48^T7+<R2?GP/10H[5\9_M_?&\^*/%4'P]TF8R:;HT@FU$Q<^=>$
M?+%QU\L'I_>;U6OHI6PN&O4UD^_?_@'X9AXRXBS]4\!>G0@[KET48JR;27PN
M3[=7KU%^ 'CGQ#^U!X\U3P5XNTRPO_ 4UE+.^GVME% FC!2/(-O(BAD.<)U.
M1D]C7VOKWPK\)ZSX#N?"<V@V*:"ULT*6D<"JL0VX#)@?*PZAASGFN _9'^"
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M^6,>6^_^>GW7WU\CT(U:*PKKUZOMO9M.-T]&T[0?,M;OWG'6*4&D_>.T\%?
M7P-X&T\P6F@6E_>2_-=:IJD2W5Y=N?O/+*X+,2>?3T K@OC-\/M-^$&G7'Q3
M\"V$/A[5]$*7.JV6G((;;5K$,!/%-$N%+A"75\;@R]>:9\=/C+JVC?%CX?\
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MK],_V!_^3<M,_P"PA>_^CC7YF3$-/*0<@NQ!'?DU^F?[ _\ R;EIG_80O?\
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M'5$@V[?+%SC=TXS][WSS5WPQ^U]\4_"'@N+PQI^OQ_88(O(M[FXMEENK>/&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>mmsi-20240701xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmsi-20240701xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "" G # 2(  A$! Q$!_\0
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MH7R'^*C[:GK0!K?:![4Y;A<\UC_;E]Z/MZ^] &T+B,_Q4\2*>C#\ZPOMR^]
MOU]Z /D+_AXQX:'7P3K0_P"WJ&G#_@HQX9_Z$K6O_ J"OALQCN,TPP@U\K_:
M-?N?TA_J3D__ #[?_@3/NC_AXMX9/_,DZU_X%PTC?\%%/#!_YDG6O_ J"OA4
MPD'@TAW#J,T?VA7[_@3_ *E9/_S[?_@3/NAO^"B'A@_\R3K7_@5!4;?\%"O"
MS<_\(3K0/J+J$5\-;_48I0P/>C^T*_</]2\E_P"?;_\  F?<P_X*):!&/W?A
M'75'I]KA-2+_ ,%'M%7KX.U=O]ZX@KX7HH^OU^X_]2LF_P"?;_\  F?=B_\
M!2/P_P#Q^!M7;Z7<(I3_ ,%(_"YZ^!=;!]KN"OA+;1LI_P!H8CO^ GP5D_\
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M/O9?^"DGAQ/^9+UD_6[@J5?^"E7AD#GP3K/X7<%? GET;*/K]?O^ /@S)_\
MGV__  )GW\O_  4J\+'_ )DG61];N"E/_!2KPO\ ]"5K/_@7!7P!Y='E4?VA
M7[_@+_4O)_\ GV__  )GW]_P\L\+#_F2M9_\"H:/^'EOA7_H2=:S_P!?4-?
M.SVH"X[4_P"T*_?\ _U+R?\ Y]O_ ,"9]^_\/+_"HZ>"-;_\"H:/^'F7A?\
MZ$;6S_V]05\" #N*7"^@I?VA7[_@/_4K)W]A_P#@3/OG_AYEX9_Z$36S_P!O
M4%-/_!3'P\?N^ ]8'N;N&O@H &G!12>8XCO^ UP3D_\ (_\ P)GW@W_!2W13
M]WP/JR_]O4-1M_P4GTAO^9.U=?I<05\)X%:][X:GL/#>DZT\J-!J,L\4<8!W
M*8BH)/UW#'TH688A]0EP;DL&E*#UT7O/U_0^T&_X*/:0YY\)ZV/I<P"F-_P4
M3T&0_-X2UYO^WN&OA[ HQ2_M#$=_P-/]2<F_Y]O_ ,"9]O?\/"?#)^]X,UUO
MK>0TY?\ @H1X5'7P/K1/O=PU\/T4?VAB.X_]2<F_Y]O_ ,"9]R+_ ,%#?"J_
M\R1K(_[>H*D'_!1+PMV\$:U_X%P5\+T4?VAB.X?ZDY-_S[?_ ($S[J'_  45
M\+CC_A"-:_\  J&E'_!1CPN.G@G6?_ J"OA7CWH('>C^T,1W_ /]2<F_Y]O_
M ,"9]U_\/&?#'_0D:U_X%PTO_#QKPS_T)&M#_M[@KX2X]:-WO1_:&([_ ("_
MU)R7_GV__ F?=O\ P\;\,C_F2-;_ / N"E_X>-^&1_S)&M'_ +>X:^$,B@MF
MC^T<1W_ /]2<E_D?_@3/O#_AXYX9_P"A(UK_ ,"H*/\ AX]X9[^"-:_\"X*^
M#B:-V.]']H8CO^ O]2<E_P"?;_\  F?>(_X*/>&?^A(UKZ_:X*/^'COAK_H2
M-:_\"X*^#L^])FC^T,1W_ /]2LF_Y]O_ ,"9]XG_ (*.^&L\^"=:_P# N"F_
M\/&_#1_YDG6O_ N"OA#<*3>*/[0Q'?\  /\ 4K)?^?;_ / F?=Y_X*-^&O\
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MAB._X#_U)R;_ )]O_P "9]X+_P %'O"8Z^ M8'_;U!4@_P""C?A,]/ FK_\
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M;B=W0D8QCO5/VJO(RI/+ZG+12=VV^NC>G_#&G!\2_#.EW^GM!I@O(50K?/\
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M\5BUA)1YHWB^O;Y6/(/MMTUH+0W,YM V\6_FMY8;UVYQGWH:]NC))(;J<R2
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MNTS.[9Y."-J+U)[#M6OJWP]M-+\.V&J'5UN8Y)%2\>W"2QVFXD?,%??GCC(
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MW[5'ZT?V?A^WXA_KOG?_ #\7_@*/@?\ X=S>,"/^1IT7_OB7_"D_X=S>,/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mmsi-20240701.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/1/2024 12:25:29 PM-->
<!--Modified on: 7/1/2024 12:25:29 PM-->
<xsd:schema targetNamespace="http://www.meritmedical.com/20240701" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:mmsi="http://www.meritmedical.com/20240701" xmlns:rxp="http://xbrl.sec.gov/rxp/2024" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mmsi-20240701_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mmsi-20240701_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mmsi-20240701_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/1/2024 12:25:29 PM-->
<!--Modified on: 7/1/2024 12:25:29 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mmsi-20240701_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/1/2024 12:25:29 PM-->
<!--Modified on: 7/1/2024 12:25:29 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mmsi-20240701.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638554335299185684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638554335299185684" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638554335299185684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638554335299185684" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638554335299185684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638554335299185684" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638554335299185684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638554335299185684" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638554335299185684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638554335299185684" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638554335299195687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638554335299195687" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638554335299195687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638554335299195687" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638554335299195687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638554335299195687" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638554335299195687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638554335299195687" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638554335299195687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638554335299195687" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638554335299195687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638554335299195687" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638554335299195687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638554335299195687" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638554335299195687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638554335299195687" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638554335299195687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638554335299195687" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638554335299205666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638554335299205666" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638554335299205666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638554335299205666" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638554335299205666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638554335299205666" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638554335299205666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638554335299205666" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638554335299205666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638554335299205666" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638554335299205666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638554335299205666" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638554335299205666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638554335299205666" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638554335299205666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638554335299205666" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140083849921456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  01,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-18592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MERIT MEDICAL SYSTEMS INC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0447695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West Merit Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Jordan<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">253-1600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MMSI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000856982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M'5#T^)VSK3XZ)_95EE*^V,8T'CB>)6()BXR5H'!X96.6)%8)./XYB#KE,^W
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ I$OA6)E<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" "D2^%8[AL:/%($  "N$   &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ I$OA6)^@&_"Q @  X@P   T
M             ( !E@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "D2^%8
MEXJ[',     3 @  "P              @ %R#P  7W)E;',O+G)E;'-02P$"
M% ,4    " "D2^%8'#AEZC\!   \ @  #P              @ %;$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ I$OA6"0>FZ*M    ^ $  !H
M         ( !QQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ I$OA6&60>9(9 0  SP,  !,              ( !K!(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ]A,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mmsi-20240701x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mmsi-20240701.xsd</File>
    <File>mmsi-20240701_lab.xml</File>
    <File>mmsi-20240701_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="mmsi-20240701x8k.htm">mmsi-20240701x8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mmsi-20240701x8k001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mmsi-20240701x8k.htm": {
   "nsprefix": "mmsi",
   "nsuri": "http://www.meritmedical.com/20240701",
   "dts": {
    "schema": {
     "local": [
      "mmsi-20240701.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mmsi-20240701_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mmsi-20240701_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "mmsi-20240701x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mmsi-20240701x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mmsi-20240701x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0000856982-24-000065-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000856982-24-000065-xbrl.zip
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MY8^I&!)$HR3I;Q)\W5EPONR[[GJ][J[/NY3-A<&9YWYY&(Z#!8I]!Y.$^R1
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MQC$E?<.U' ,@XM, DV7?6',3<A]CX^.'GW]Z_,4TOSV]O8" ^NL($0%\AJ!
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MJ!7"YQ N"[3/M#=#\\N4M=9EY?&CG?^R17T.9>^UP?L/0S[\#5!+ P04
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M)P1]3BETZ5 :6"8L[XHL__N@1TTT"R2;-0-XDDIG)L\\J]6>/'1]"RD! ]E
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MFN_$ [=)@C;#1J$'9@P 7!D:;>JT&"D9 8'72B&M;05!"OPE6L((U@WKN5Y
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M?,'B73I"!H&NQP*@Y Z@N1&$R.W,#VUD7YOUF<U!@S=6'Y3.'CHV7.!Q QO
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MHQG@5:&VB]%JL'Z(@69<@/X6%[PM,ETF(=/B7TWX1Y9?.W:T@.[CF(\!'\%
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M+FIP9[5Y=U!3W[?O0:ITI$I5 6D"2J^)R!<0$!"07B)B 4*1'FH4!)0J74!
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MEX'<N3IRU#Y 9)<%VR%VG0=#':4IUBF NL</5_'X+Z-;!;G !SH.:\]5>8@
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M37,UNJ8E9GSRZW!F!RVA.Y0;K[LL 6&UV_8/%9YP_0 5RJ&(Y.(-4^OZDC1
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MT<IP)*UH_IO_GP^8./O? %!+ P04    " "D2^%8J(;HKE,N  #_D $ &
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M(:@X-RT0MKCN CN(&N<C-*H\(%<* [8Q!1Z4:JAQ;V#!=6A1GXTM)O/&#&"
MFRBE/=P,GVBZT*<.2?#OV+ZN>T<P"/>50._+_DJ \H@:>!1 >^@A<2KXU$D"
M+CZV.#DUV:NM0[WW)-(':-=206,^2MQY]Y..:S[/RT8WDXN45B!53 %"S=_4
M0J='F[L\*X$:U8!/1ZEA )TB$;A3FUYA&#JD[V;R,A)<)1$Z]Q/ /LJ-Y-BB
M>Q!2)4H>1<4U$2?$J8%G,!R>@HNC,18DG?"'M(%/I@'+=S 9X<1A%(&6+RXT
MS6&/G 5\!'?^WZ_^MV:[TVQV.LT#3$GP]-#2%;+L!&48+&),-A\H"%1UP;ZD
M<0\ARQ+"@"*A1>,4@; %E$;R!6',^ V7/CV(V "4"F@)6J[ I.)%T0?]LFFJ
M#0&3,RMO+[0Y]Z2'Q,EA]&N+D>XYV_<1Q"E=_E[2(^<E^)='Q!"US"TAC)T/
M3D" 0%5A6#K#JO$FRJF/(!;DD\(6-1V- ;1IDP\-):[0H9CIC0(^#*9<GBCT
M"(";P&Z/2(1!$8@5YFVIOF&D)$EXP3W2$VJ8ZK]-Q0(JN)&*\K=:62 :IQ"P
M#.K"N%T8%M@E#.Z@+3JS&V3 Q_P#>)\P\ 58O@_01YB.B+VY/O_ 6D[CK<,N
M!9X@C![26H'%X>\<2Y#()U@L@C3XJ!=N,""EU HN$(>NT7@@+*[> &;/8IIQ
MQ-T8F:&](GHW"F1ON)_PU&V"U 'LU7#>L 4O^QAVP7SU1#!&A2& P@,D0<+D
MJ&F" (E< KXE2$ %PS%)/AUTI$%G+IVR:/('3KNS*+G26NF*\O+FQM('&<1]
M1=@,1*]'\5,:4$4ZCS,$9N%_!'A2CI@#HCM:.^ Y00,2BB@R"Q,*HUUH3Y+#
M?*#PN3 HD+SW6J[Q5PV9A_%H!(Y6(V*[#FC%"=A-?-?#%2'F22"8[:&](Y#9
MTX?CHP1E >" CV'&\40 HAU1XC"3*XPYK2+54QKT"X.]*U'UTN'**S@#(L,I
M5\D(IC(]?MZCXU\TY,,L%V6"5>98*"57FJ9E Q$@N!1S2W>M@Y*E.X;'.FKA
MG2 EZB,8W1"QK P]M&;0SGLPU:,>/-;6Z+^M,V_I8.S@(AN;:25- S>1K1/J
M%7<=*#$ROO$P"I/!<*Z3O9H-MD"Y!Q2%_MAL8[L_-M-4M=;,F7XI^A0S&:,Q
M# &3C4 (P&;"Y63%%P+RTH"P& _.X_Z:AM;D(.<S["VGDZ>_3L^2[0%P87M
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M.BBG0%0;NM^(%_"('D3VN!M&P!.RL#@A>G7FD=R45.+'* EDGW'.*3G<,(F
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MH!#JQD*E1>&&ZK@B2X'8C5ZSH*1@>6&?U=<YX4DBE4@:NFU)Z6I![?H24$<
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M_'?_'U!+ 0(4 Q0    ( *1+X5C*3)/ZE ,  .,,   1              "
M 0    !M;7-I+3(P,C0P-S Q+GAS9%!+ 0(4 Q0    ( *1+X5A'JP52:04
M .X[   5              "  <,#  !M;7-I+3(P,C0P-S Q7VQA8BYX;6Q0
M2P$"% ,4    " "D2^%8TEF9QG8$  #[)0  %0              @ %?"0
M;6US:2TR,#(T,#<P,5]P<F4N>&UL4$L! A0#%     @ I$OA6$]+#BW]'P
MN-@  !0              ( !" X  &UM<VDM,C R-# W,#%X.&LN:'1M4$L!
M A0#%     @ I$OA6-O_B\1W*P  "RT  !<              ( !-RX  &UM
M<VDM,C R-# W,#%X.&LP,#$N:G!G4$L! A0#%     @ I$OA6*B&Z*Y3+@
M_Y ! !@              ( !XUD  &UM<VDM,C R-# W,#%X97@Y.60Q+FAT
7;5!+!08     !@ & )(!  !LB      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>mmsi-20240701x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mmsi-20240701.xsd" xlink:type="simple"/>
    <context id="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000856982</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Tc_i_pX9bOrak-B4BEsX_Sj5g_2_1">0000856982</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Tc_sQqph26fYUSZHwOUnHSjQQ_3_1">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Hidden_pYJls-55kkux-oHecHJSjQ">MERIT MEDICAL SYSTEMS INC</dei:EntityRegistrantName>
    <dei:DocumentType
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Narr_P1RX9SbtVkS5WWCaHw68dg">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Narr_tM4YxHx-4kuwH7IUR3tBdQ">2024-07-01</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Tc_FTsM-g86wUi02lVDOQhudA_1_0">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Tc_HxLe-KpLPUq6nZ2XnySRcg_1_2">0-18592</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Tc_FMbELaq2I0mXIJHakkuCQA_1_4">87-0447695</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Tc_kS_is8bVQkqLhGJon85lRg_1_0">1600 West Merit Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Narr_Hc6qjCrGTEKRnf33hFq-Hg">South Jordan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Narr_-x6EaZKFCkmeT_nV7l4JQQ">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Tc_Hn8jQwmiEE-n-3r81lG68Q_2_2">84095</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Narr_yYgtQiVQeECS0bD2pecAfA">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Narr_-wP1Btmd5U2rQP9ovOYC3w">253-1600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Narr_elJjpXYbt0aCo3jTpcgACA">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Narr_7ss1jZzLqUGKfAVGZTuYVA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Narr_k_KLlDbtjEKT6RzzYQTudA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Narr_oNIyKZtWDUWSMxZ6Q75-wQ">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Tc_sN-qQMH8DEWIU7of4jvcdg_2_0">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Tc_1iSQgvWa8kqoxIaRRi2V3A_2_2">MMSI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Narr_xly9DxZ8X0a8xHWB4kI4xg">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_1_2024_To_7_1_2024_mD_1VK8vGkSvmkrj88q0lw"
      id="Narr_pa2-Xs1vukeGz5KIpODOsQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
